NUREXONE BIOLOGIC INC.

Communiqués NurExone Biologic Inc.

Actions

NRX

CA67059R1091

Temps Différé Toronto S.E. Autres places de cotation 21:31:46 04/06/2024			Varia. 5j.	Varia. 1 janv.
0,46 ^CAD	-9,80 %		-6,12 %	+55,93 %

25/04	NurExone Biologic annonce son inscription à l'OTCQB et son admissibilité au DTC	MT
02/04	NurExone Biologic Inc. déclare ses résultats pour l'année complète terminée le 31 décembre 2023	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials	29/05	AQ
NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations	17/05	AQ
NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility	25/04	AQ
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine	22/04	AQ
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine	19/04	AQ
NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update	02/04	AQ
Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise	27/03	AQ
In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN	22/03	AQ
NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence	15/03	AQ
NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel	08/03	AQ
NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit	01/03	AQ
NurExone’s Intellectual Property Portfolio Expands	20/02	AQ
NurExone Launches Licensing Efforts for ExoTherapy Platform	14/02	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

-40% Prolongation exceptionnelle : Nos abonnements vous guident vers les meilleurs investissements de demain.

PROFITEZ-EN MAINTENANT